

**Aviron**

● 297 North  
Bernardo Avenue  
Mountain View  
California  
94043

**FluMist™ Briefing Document**

tel  
**650.919.6500**  
fax  
**650.919.6610**

**FluMist™**  
Influenza Virus Vaccine, Trivalent, Types A & B,  
Live, Cold Adapted

**Briefing Document**

Vaccines and Related Biological Products  
Advisory Committee Meeting

July 26-27, 2001

Aviron  
297 North Bernardo Avenue  
Mountain View, CA 94043

Aviron waives confidentiality of the data contained in these presentation materials. Aviron grants the FDA the authority to release these presentation materials to the public through electronic or other means deemed appropriate.

**Table of Contents**



## TABLE OF CONTENTS

<b>LIST OF ABBREVIATIONS .....</b>	<b>vi</b>
<b>LIST OF TABLES .....</b>	<b>vii</b>
<b>LIST OF FIGURES.....</b>	<b>xi</b>
<b>1. INTRODUCTION .....</b>	<b>1</b>
<b>1.1. Overview.....</b>	<b>1</b>
<b>1.2. Product Information.....</b>	<b>1</b>
<b>2. EPIDEMIOLOGY AND PREVENTION OF INFLUENZA.....</b>	<b>3</b>
<b>2.1. Epidemiology of Influenza.....</b>	<b>3</b>
<b>2.2. Prevention of Influenza with Licensed Vaccine .....</b>	<b>4</b>
<b>3. RATIONALE FOR FLUMIST DEVELOPMENT .....</b>	<b>6</b>
<b>4. FLUMIST CLINICAL PROGRAM.....</b>	<b>8</b>
<b>5. SUMMARY OF EFFICACY .....</b>	<b>15</b>
<b>5.1. Introduction.....</b>	<b>15</b>
<b>5.1.1. Clinical Efficacy Versus Clinical Effectiveness of Vaccination .....</b>	<b>17</b>
<b>5.1.2. Statistical Methods .....</b>	<b>18</b>
<b>5.2. Healthy Adults.....</b>	<b>19</b>
<b>5.2.1. Efficacy of FluMist in Healthy Adults (Challenge Study AV003) .....</b>	<b>19</b>
<b>5.2.2. Effectiveness of FluMist in Healthy Adults (Study AV009) .....</b>	<b>22</b>
<b>5.2.3. Conclusions .....</b>	<b>25</b>
<b>5.3. Healthy Children .....</b>	<b>26</b>
<b>5.3.1. Efficacy in Healthy Children (Study AV006) .....</b>	<b>26</b>
<b>5.3.2. Efficacy of FluMist Against H1N1 (Vaccine Challenge Study AV011) .....</b>	<b>38</b>
<b>5.3.3. Conclusions .....</b>	<b>41</b>
<b>5.4. Efficacy Conclusions.....</b>	<b>41</b>
<b>6. SUMMARY OF IMMUNOGENICITY.....</b>	<b>45</b>
<b>6.1. Introduction .....</b>	<b>45</b>
<b>6.1.1. Immunological Assays .....</b>	<b>48</b>

<b>6.2. Immunogenicity of FluMist in Adults.....</b>	<b>49</b>
6.2.1. Study Designs and Demographics.....	49
6.2.2. FluMist Adult Dosage and Regimen.....	49
6.2.3. Relationship Between Immunogenicity and Efficacy in Adults.....	50
6.2.4. Conclusions from Immunogenicity Studies with FluMist in Adults .....	53
<b>6.3. Immunogenicity of FluMist in Children .....</b>	<b>53</b>
6.3.1. Study Designs and Demographics.....	53
6.3.2. Dose Escalation Studies .....	54
6.3.3. Consistency of the Immune Response to FluMist .....	75
6.3.4. Conclusions from Immunogenicity Studies with FluMist in Children .....	80
<b>7. SUMMARY OF SAFETY .....</b>	<b>81</b>
<b>7.1. Introduction.....</b>	<b>81</b>
7.1.1. Methods.....	81
<b>7.2. Participant Exposure .....</b>	<b>83</b>
<b>7.3. Overview of FluMist Safety.....</b>	<b>84</b>
7.3.1. Overall Demographic Characteristics.....	85
7.3.2. Overall Serious Adverse Events .....	88
7.3.3. Participants Withdrawn from Study Because of an Adverse Event.....	91
<b>7.4. Safety in Healthy Adults (18–64 Years of Age).....</b>	<b>91</b>
7.4.1. Serious Adverse Events .....	91
7.4.2. Demographics .....	92
7.4.3. Reactogenicity .....	92
7.4.4. Reactogenicity by Gender .....	93
7.4.5. Reactogenicity by Race/Ethnicity.....	94
7.4.6. Number of Days and by Day Analysis of Reactogenicity.....	96
7.4.7. Other Analyses During the Reactogenicity Period .....	98
7.4.8. Summary .....	100
<b>7.5. Safety in Healthy Children (1–8 Years of Age).....</b>	<b>101</b>
7.5.1. Serious Adverse Events – Initial Vaccination Year.....	101

7.5.2.	Demographics .....	101
7.5.3.	Reactogenicity During Initial Vaccination Year.....	102
7.5.4.	Other Analyses During the Reactogenicity Period .....	107
7.5.5.	Other Adverse Events – Initial Vaccination Year.....	110
7.5.6.	Reactogenicity by Age.....	110
7.5.7.	Reactogenicity by Gender .....	112
7.5.8.	Reactogenicity by Race/Ethnicity.....	112
7.5.9.	Safety of Annual Administration of FluMist in Children (1–8 Years of Age).....	114
7.5.10.	Summary.....	117
<b>7.6.</b>	<b>Safety in Healthy Children and Adolescents (9–17 Years of Age).....</b>	<b>118</b>
7.6.1.	Serious Adverse Events .....	118
7.6.2.	Demographics .....	118
7.6.3.	Reactogenicity and Other Adverse Events.....	118
7.6.4.	Summary .....	118
<b>7.7.</b>	<b>Safety in Healthy Children and Adolescents 1–17 Years of Age in Study AV019: Interim Data .....</b>	<b>119</b>
7.7.1.	Study Design .....	119
7.7.2.	Statistical Methods .....	119
7.7.3.	Enrollment .....	120
7.7.4.	Demographics .....	121
7.7.5.	Overview Of Safety.....	121
7.7.6.	MAEs Associated With Increased Relative Risk in FluMist Recipients....	126
7.7.7.	MAEs Associated with Decreased Relative Risk in FluMist Recipients ...	133
7.7.8.	Summary .....	134
<b>7.8.</b>	<b>Safety Results by High-Risk Population .....</b>	<b>134</b>
7.8.1.	Safety of FluMist in Participants with Asthma .....	135
7.8.2.	Safety of FluMist in HIV-Infected Children .....	140
7.8.3.	Safety of FluMist in HIV-Infected Adults.....	144
7.8.4.	Safety in Adults with COPD .....	146

7.8.5. Safety in Adults ≥65 Years of Age .....	146
<b>7.9. Other Safety Information .....</b>	<b>148</b>
7.9.1. Drug/Vaccine Interactions.....	148
7.9.2. Overdose, Abuse or Misuse.....	148
7.9.3. Safety of FluMist in Pregnant Women.....	148
7.9.4. Effects of Long-Term Exposure .....	148
7.9.5. Transmission .....	149
<b>7.10. Safety Summary.....</b>	<b>150</b>
<b>7.11. Safety Conclusions.....</b>	<b>151</b>
<b>8. OVERALL CONCLUSIONS .....</b>	<b>153</b>
<b>APPENDICES .....</b>	<b>154</b>

**Appendix 1: Pre-Specified Medically Attended Events in Study AV019**

**Appendix 2: MAE Categories (N=147) Recorded in Hospital, ED, or Outpatient Clinic Databases for Study Participants during the Safety Evaluation Period in Study AV019**